The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

deep PSA decline

23rd Sep 2024

Prostate-specific antigen levels and quality of life in advanced prostate cancer patients treated with apalutamide: a plain language summary of the SPARTAN and TITAN trials

This summary describes the results from an additional (or post hoc) analysis of the TITAN study. The TITAN study looked at whether the prostate cancer treatment apalutamide could be used to treat individuals with metastatic castration-sensitive prostate cancer (or mCSPC).

22nd Jan 2024

The TITAN study: a plain language summary looking at how PSA decline with apalutamide therapy is associated with longer survival and improved outcomes in people with metastatic prostate cancer